Open AccessTen-Year Update of a Randomized, Prospective Trial of Conventional Fractionated Versus Moderate Hypofractionated Radiation Therapy for Localized Prostate Cancer
Author(s) -
Vladimir Avkshtol,
Karen Ruth,
Eric A. Ross,
M.A. Hallman,
Richard E. Greenberg,
R Price,
B.K. Leachman,
Robert G. Uzzo,
C Ma,
David Chen,
Daniel M. Geynisman,
M.L. Sobczak,
Eddie Zhang,
J.K. Wong,
Alan Pollack,
Eric M. Horwitz
Publication year - 2020
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.19.01485
Subject(s) - medicine , prostate cancer , cumulative incidence , androgen deprivation therapy , radiation therapy , clinical endpoint , randomized controlled trial , prospective cohort study , incidence (geometry) , lymph node , cancer , surgery , cohort , physics , optics
The previously published single institution randomized prospective trial failed to show superiority in the 5-year biochemical and/or clinical disease failure (BCDF) rate with moderate hypofractionated intensity-modulated radiation therapy (H-IMRT) versus conventionally fractionated IMRT (C-IMRT). We now present 10-year disease outcomes using updated risk groups and definitions of biochemical failure.